4 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 4 | Terminated 4 |
Follow Tumors: new trials by email Literature Review of Tumors trials Research Report on Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Study of BMS-663513 in Patients With Advanced Cancer BMS-663513 - Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 115 | 2005-12-01 | 2015-10-12 |
| Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates Epirubicin, Carboplatin, Capecitabine - Gastric Cancer, Esophageal Cancer | Phase 1 / Phase 2 | Terminated | AHS Cancer Control Alberta | 50 | 2005-10-01 | 2016-02-15 |
| Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary Capecitabine, Carboplatin, Paclitaxel - Tumors, Unknown Primary Tumors | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 57 | 2005-06-01 | 2016-09-23 |
Neoplasms (4) · Adenocarcinoma (1) · Esophageal Neoplasms (1) · Neoplasms, Unknown Primary (1) · Stomach Neoplasms (1)
Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Stomach Diseases (1)
Capecitabine (2) · Carboplatin (2) · Epirubicin (1) · Ipilimumab (1) · Nivolumab (1) · Paclitaxel (1) · Tetanus Toxoid (1) · urelumab (1)
Bristol-Myers Squibb (2) · AHS Cancer Control Alberta (1) · Ohio State University Comprehensive Cancer Center (1)
Canada (3) · United States (3) · France (1) · Spain (1) · Switzerland (1)
Michael Sawyer, MD (1) · Tony Bekaii-Saab (1)
2017 (1)